Testing effectiveness (Phase 2)Study completedNCT03108066
What this trial is testing
MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)
Who this might be right for
VHL Gene MutationVHLVHL Syndrome+8 more
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 4